VERA Live signals | Maximize Profits with Getagraph.com

SELL 4893 min ago

@ $14.07

Issued: 28 Sep 2023 @ 14:03

Return: -2.56%

Previous signal: Sep 26 - 15:26

Previous signal: Buy

Return: -10.78 %

Live Chart Being Loaded With Signals

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States...

Stats
Today's Volume	421 586
Average Volume	468 287
Market Cap	607.61M
Next earnings date	2023-11-08 ( $-0.500)
P/E	-4.68
ATR14	$0.749 (5.47%)

Volume Correlation

Long: 0.51 (weak)

Short: -0.39 (neutral)

Signal:(34) Neutral

Vera Therapeutics, Inc. Correlation

10 Most Positive Correlations
LCAP	0.928
VTIP	0.912
CYTO	0.907
PAIC	0.896
MTEX	0.892
GAINL	0.889
RMRM	0.886
PROC	0.886
WNW	0.884
OP	0.873

10 Most Negative Correlations
SCR	-0.952
BOCH	-0.924
NETE	-0.919
KIN	-0.914
SHSP	-0.904
IPHA	-0.899
DGLY	-0.898
SRRA	-0.898
THCPU	-0.898
ICON	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Vera Therapeutics, Inc. Correlation - Currency/Commodity

-0.07
( neutral )

-0.28
( neutral )

0.00
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.49
( neutral )

Vera Therapeutics, Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-3.35

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.460

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.790

Q4	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-1.220

Vera Therapeutics, Inc.

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

Estimated
VERA Next Dividend
(Unknown) $0 Probabilty 0 %

Quarter Ratio
VERA 0.00 0.00

Pay Frequency
VERA Insufficient data to determine frequency 0

Yearly Payout
VERA